{"id":"382a3818-0cfb-532c-a7d0-26042faf9eb8","stable_key":"e3f6ce02-0bd7-5103-acc1-68503ab6751b:cancer-labeling","predicate":"reported_relationship","statement":"Labeled ALCAR supplied approximately 5–8% of measured cellular acetyl-CoA in the 2026 tracing experiment.","claim_class":"observational","status":"source_recorded","evidence_grade":"ungraded","direction":"neutral","is_public":true,"mechanism_event_id":"50d45708-d859-5c5c-aa0e-a6993f0d7ea7","mechanism_event_label":"Labeled ALCAR supplied approximately 5–8% of measured cellular acetyl-CoA in the 2026 tracing experiment.","subject":{"id":"5ce394a9-6ec6-56dd-866f-37d85c0556e4","slug":"acetylcarnitine","display_name":"Acetyl-L-carnitine","entity_type_key":"small_molecule"},"object":{"id":"21fe8d16-9e46-5850-bbce-067aa15e92f1","slug":"human-cancer-alcar-acetylcoa-labeling","display_name":"Human cancer-cell acetyl-CoA labeling from ALCAR","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"50d45708-d859-5c5c-aa0e-a6993f0d7ea7","stable_key":"e3f6ce02-0bd7-5103-acc1-68503ab6751b:cancer-labeling-event","event_type":"experimental_observation","label":"Labeled ALCAR supplied approximately 5–8% of measured cellular acetyl-CoA in the 2026 tracing experiment.","description":"### cancer-labeling\n\nLabeled ALCAR supplied approximately 5–8% of measured cellular acetyl-CoA in the 2026 tracing experiment.\nA fraction of a measured pool is not a whole-body uptake percentage or a flux independent of labeling time. It cannot be extrapolated to oral dosing.\nModel and exposure: 13C2-acetylcarnitine tracing; Extended Data Fig. 6a.\nLimitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.\nReference: αKG-mediated carnitine synthesis drives DNA repair via histone acetylation. | 2026 | https://pubmed.ncbi.nlm.nih.gov/42203879/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC13307467/ | https://doi.org/10.1038/s41586-026-10584-7 | Access: Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"5ce394a9-6ec6-56dd-866f-37d85c0556e4","slug":"acetylcarnitine","display_name":"Acetyl-L-carnitine","entity_type_key":"small_molecule"},"role":"recorded factor","stoichiometry":null,"state_label":"as reported","sequence_order":0,"notes":""},{"entity":{"id":"21fe8d16-9e46-5850-bbce-067aa15e92f1","slug":"human-cancer-alcar-acetylcoa-labeling","display_name":"Human cancer-cell acetyl-CoA labeling from ALCAR","entity_type_key":"cellular_process"},"role":"measured outcome","stoichiometry":null,"state_label":"not_reported","sequence_order":1,"notes":""},{"entity":{"id":"b7ed6e4c-e560-5cee-b68f-895f21862e6f","slug":"acetyl-coa","display_name":"Acetyl-CoA","entity_type_key":"small_molecule"},"role":"labeled product","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""}]},"contexts":[{"dimension":"evidence_access","value_text":"Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"13C2-acetylcarnitine tracing; Extended Data Fig. 6a.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"interpretation_status","value_text":"Source-derived curation with stated access limits; ungraded, not independent replication.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Acetyl-L-carnitine collection; exact intervention and molecular form govern interpretation.","comparator":null,"unit":null,"notes":"","entity":{"slug":"acetylcarnitine","display_name":"Acetyl-L-carnitine","entity_type_key":"small_molecule"}},{"dimension":"plain_language","value_text":"Labeled ALCAR supplied approximately 5–8% of measured cellular acetyl-CoA in the 2026 tracing experiment.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"αKG-mediated carnitine synthesis drives DNA repair via histone acetylation. | https://pubmed.ncbi.nlm.nih.gov/42203879/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC13307467/ | https://doi.org/10.1038/s41586-026-10584-7","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"source_locator","value_text":"Reviewed reference cancer-labeling; A fraction of a measured pool is not a whole-body uptake percentage or a flux independent of labeling time. It cannot be extrapolated to oral dosing.","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"8eba6d08-8e9d-5fa8-b757-72b07140551d","evidence_kind":"source_excerpt","locator":"Lines 312-318","start_line":312,"end_line":318,"excerpt":"### cancer-labeling\n\nLabeled ALCAR supplied approximately 5–8% of measured cellular acetyl-CoA in the 2026 tracing experiment.\nA fraction of a measured pool is not a whole-body uptake percentage or a flux independent of labeling time. It cannot be extrapolated to oral dosing.\nModel and exposure: 13C2-acetylcarnitine tracing; Extended Data Fig. 6a.\nLimitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.\nReference: αKG-mediated carnitine synthesis drives DNA repair via histone acetylation. | 2026 | https://pubmed.ncbi.nlm.nih.gov/42203879/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC13307467/ | https://doi.org/10.1038/s41586-026-10584-7 | Access: Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.","model_system":"13C2-acetylcarnitine tracing; Extended Data Fig. 6a.","directness":"reported_statement","verification_status":"source_recorded","notes":"Original paraphrase in the retained reviewed reference, not a verbatim primary-paper quotation. Access level is explicit.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"2588f904-245a-597a-8a12-65118013fb90","stable_key":"import-e3f6ce02-0bd7-5103-acc1-68503ab6751b","title":"Acetyl-L-carnitine: detailed mechanisms of action (reviewed 6 October 2026)","document_type":"imported_text","citation_label":"AI-assisted original review of primary studies and clearly identified official records. Exact primary access is stated; no independent replication is claimed.","file_path":"","sha256":"84cc82d6fbb0fd5d73c4ce779e9f88e7f0184ba2d29b18ad0f153815380f2975","revision_id":"dac7a950-dbe5-5c7a-9c70-2ea711d5c71a","review_status":"source_recorded","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}